Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision | ||
helene_decaluwe [2022/05/22 15:12] liam | helene_decaluwe [2022/09/20 03:45] (current) liam [COVID-19] | ||
---|---|---|---|
Line 10: | Line 10: | ||
She then completed her training in pediatric clinical immunology at the [[Necker Enfants-Malades Hospital]] in Paris, France with Professor [[Alain Fischer]]. Her research training includes a Master and a PhD degree in immunology at [[Pierre and Marie Curie University]] carried out in the laboratories of Professor [[Jean-Laurent Casanova]] and Professor [[James Di Santo]] respectively. | She then completed her training in pediatric clinical immunology at the [[Necker Enfants-Malades Hospital]] in Paris, France with Professor [[Alain Fischer]]. Her research training includes a Master and a PhD degree in immunology at [[Pierre and Marie Curie University]] carried out in the laboratories of Professor [[Jean-Laurent Casanova]] and Professor [[James Di Santo]] respectively. | ||
+ | |||
===== Career and Affiliations ===== | ===== Career and Affiliations ===== | ||
Line 19: | Line 20: | ||
Decaluwe is a member of the [[National Advisory Committee on Immunization]] (NACI).((Public Health Agency of Canada. (2022, February 25). //National Advisory Committee on Immunization (NACI): Membership and representation.// | Decaluwe is a member of the [[National Advisory Committee on Immunization]] (NACI).((Public Health Agency of Canada. (2022, February 25). //National Advisory Committee on Immunization (NACI): Membership and representation.// | ||
+ | |||
+ | ===== Consulting ===== | ||
+ | |||
+ | Decaluwe was invited in April 2021 by [[pharmaceutical_companies: | ||
===== Research ===== | ===== Research ===== | ||
Line 27: | Line 32: | ||
She is funded by the [[Fonds de Recherche du Québec en Santé]] (FRQS), [[Canadian Institutes of Health Research]], [[National Institutes of Health]], [[Canadian Cancer Society]], [[Cole Foundation]], | She is funded by the [[Fonds de Recherche du Québec en Santé]] (FRQS), [[Canadian Institutes of Health Research]], [[National Institutes of Health]], [[Canadian Cancer Society]], [[Cole Foundation]], | ||
+ | |||
+ | She has also receiving funding from [[pharmaceutical_companies: | ||
==== COVID-19 ==== | ==== COVID-19 ==== | ||
Decaluwe is a co-investigator on a research grant titled " | Decaluwe is a co-investigator on a research grant titled " | ||
+ | |||
+ | She has applied for the CIHR-CEPI Leadership Award for Excellence in Vaccine Research for Infectious Diseases of Epidemic Potential, administered by the [[Canadian Institutes of Health Research]] and [[Coalition for Epidemic Preparedness Innovations]] (CEPI).((Public Health Agency of Canada. (2022, February 25). //National Advisory Committee on Immunization (NACI): Membership and representation.// | ||
=== RECOVER === | === RECOVER === | ||
Line 42: | Line 51: | ||
=== CHOIR === | === CHOIR === | ||
- | Decaluwe is a Principal Investigator]] in the Children and Older Teens Immune Response to SARS-CoV-2 in Montreal ([[CHOIR study]]) alongside [[Caroline Quach-Thanh]] and [[Jesse Papenburg]], | + | Decaluwe is a Principal Investigator in the Children and Older Teens Immune Response to SARS-CoV-2 in Montreal ([[CHOIR study]]) alongside [[Caroline Quach-Thanh]] and [[Jesse Papenburg]], |
+ | |||
+ | ===== Presentations ===== | ||
+ | |||
+ | Decaluwe presented at the 76th Annual [[Canadian Society of Allergy and Clinical Immunology]] Scientific Virtual Meeting on the topic of hyperinflammation and targeted immunotherapies in hemophagocytic lymphohistiocytosis.((// |